Lilly gets a date with FDA to discuss Alzheimer's med donanemab

Mark your calendars: Eli Lilly will come before the FDA’s advisory committee to discuss Alzheimer’s disease medicine donanemab June 10.

The Peripheral and Central Nervous System Drugs Advisory Committee will meet from 9 a.m. to 5 p.m. ET on that date to discuss the application for donanemab in early symptomatic Alzheimer’s, Lilly announced in a Tuesday statement.